KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares Repurchased
Ratios

Vertex Pharmaceuticals (VRTX) Receivables - Net (2016 - 2025)

Vertex Pharmaceuticals has reported Receivables - Net over the past 17 years, most recently at $2.1 billion for Q4 2025.

  • Quarterly results put Receivables - Net at $2.1 billion for Q4 2025, up 27.55% from a year ago — trailing twelve months through Dec 2025 was $2.1 billion (up 27.55% YoY), and the annual figure for FY2025 was $2.1 billion, up 27.55%.
  • Receivables - Net for Q4 2025 was $2.1 billion at Vertex Pharmaceuticals, up from $1.9 billion in the prior quarter.
  • Over the last five years, Receivables - Net for VRTX hit a ceiling of $2.1 billion in Q4 2025 and a floor of $929.1 million in Q2 2021.
  • Median Receivables - Net over the past 5 years was $1.6 billion (2023), compared with a mean of $1.5 billion.
  • Biggest five-year swings in Receivables - Net: soared 43.45% in 2022 and later grew 0.66% in 2025.
  • Vertex Pharmaceuticals' Receivables - Net stood at $1.1 billion in 2021, then grew by 26.86% to $1.4 billion in 2022, then increased by 8.4% to $1.6 billion in 2023, then grew by 2.94% to $1.6 billion in 2024, then rose by 27.55% to $2.1 billion in 2025.
  • The last three reported values for Receivables - Net were $2.1 billion (Q4 2025), $1.9 billion (Q3 2025), and $1.9 billion (Q2 2025) per Business Quant data.